title: Potential application of lithium in Parkinson's and other neurodegenerative diseases.
abstract: Lithium, the long-standing hallmark treatment for bipolar disorder, has recently been identified as a potential neuroprotective agent in neurodegeneration. Here we focus on introducing numerous in vitro and in vivo studies that have shown lithium treatment to be efficacious in reducing oxidative stress and inflammation, increasing autophagy, inhibiting apoptosis, and decreasing the accumulation of α-synulcein, with an emphasis on Parkinson's disease. A number of biological pathways have been shown to be involved in causing these neuroprotective effects. The inhibition of GSK-3β has been the mechanism most studied; however, other modes of action include the regulation of apoptotic proteins and glutamate excitotoxicity as well as down-regulation of calpain. This review provides a framework of the neuroprotective effects of lithium in neurodegenerative diseases and the putative mechanisms by which lithium provides the protection. Lithium-only treatment may not be a suitable therapeutic option for neurodegenerative diseases due to inconsistent efficacy and potential side-effects, however, the use of low dose lithium in combination with other potential or existing therapeutic compounds may be a promising approach to reduce symptoms and disease progression in neurodegenerative diseases.
authors.affiliation: Department of Biological Sciences, Delaware State University Dover, DE, USA.
authors.forename: Carol A
authors.initials: CA
authors.lastname: Lazzara
authors.affiliation: Department of Biological Sciences, Delaware State University Dover, DE, USA.
authors.forename: Yong-Hwan
authors.initials: YH
authors.lastname: Kim
keywords: Bcl-2; GSK-3β; and autophagy; calpain; neuroprotection